Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A study suggests that you should disregard the "pack-years" when determining your eligibility for lung cancer screening.

2.

Why Are These Bones and Teeth Where They Shouldn't Be?

3.

Survey: Record Numbers of US Adults Report Depression.

4.

Talc Powder Not Linked to Lung Cancer in Women

5.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot